Key Takeaways
- Billy Caldwell’s case led to changes in UK cannabis law, but access remains limited for most patients.
- Many UK patients need private prescriptions, which are costly and often inaccessible to those with chronic illnesses.
- NHS prescriptions for medical cannabis are rare, with only a few specific conditions eligible.
- The UK lags behind countries like Germany and Australia in providing accessible medical cannabis treatment.
- Despite legislative progress, the UK medical cannabis access gap persists, leaving many families in need without affordable options.
Billy Caldwell recently turned 21. He is seizure-free, thriving, and by his mother Charlotte’s account, he’s walking up steps he couldn’t manage not long ago and greeting visitors with warmth he couldn’t show before. For a young man who was having between 300 and 800 seizures a day at the height of his illness, that is a remarkable outcome.
His case is also the one that helped push the UK government to change the law. In November 2018, following public outcry over Billy’s cannabis oil being seized at Heathrow Airport, the UK updated the Misuse of Drugs Regulations 2001 to allow specialist doctors to prescribe cannabis-based medicinal products. It was framed as a turning point.
And yet Charlotte Caldwell, whose fight made that law possible, says the system still isn’t working in a recent article by BBC News. Billy receives his medicine through the NHS, something the family describes as being “blessed” to have. But for most patients in the UK seeking legal medical cannabis, the reality is sharply different. Private prescriptions can run from £400 to £1,000 a month, and the NHS pathway is so narrow that most people who qualify medically are still effectively priced out.
That’s the contradiction sitting at the center of UK cannabis policy right now. A law changed because a child nearly died without his medicine. And still, eight years later, families in similar situations are being told the same treatment is available, just not at a price they can manage.
What Did the 2018 Law Change Actually Do for UK Medical Cannabis Patients?
The November 2018 reform allowed doctors on the GMC Specialist Register to prescribe cannabis-based medicinal products (CBMPs) to patients. That was real progress, and it should not be understated. Before 2018, no legal route existed at all.
But the law did not guarantee NHS funding. It did not instruct the NHS to make CBMPs routine. It created a legal framework and then left clinical and financial decisions to a system that was not ready for them. The NHS moved cautiously, as it tends to, prioritizing the conditions where the evidence base was clearest.
According to NHS guidance, the conditions routinely eligible for an NHS prescription are three: rare severe forms of epilepsy, spasticity caused by multiple sclerosis, and nausea or vomiting from chemotherapy. In each case, the patient must have tried other treatments first, and the prescription must be initiated by a specialist hospital doctor. The bar is high by design.
The government confirmed in November 2024 that it has no plans to make further changes to this arrangement. That statement, buried in a written parliamentary response, essentially signaled that the current restricted model is not going to shift in the near term.
Why Are NHS Prescriptions for Medical Cannabis So Rare in the UK?
This is where the numbers become difficult to ignore. According to the House of Commons Library, there were around 5,000 NHS prescriptions for licensed cannabis-based medicines in the community in 2023. That figure does not include hospital or private prescriptions, but it still tells a stark story.
By contrast, private prescriptions grew from around 283,000 in 2023 to 659,000 in 2024, according to Freedom of Information data from the NHS Business Services Authority. That figure counts prescriptions, not individual patients, but using a cautious average of eight prescriptions per patient per year, the Medical Cannabis Clinicians Society estimates around 80,000 to 90,000 UK patients are currently accessing cannabis-based medicine. Almost all of them are paying privately.
Several factors drive the reluctance to prescribe on the NHS. In October 2024, the government stated plainly that “until the evidence base improves, prescribers will remain reticent in prescribing and no decision can be made by the NHS on routine funding.” Many clinicians are unfamiliar with dosing, concerned about limited clinical trial data for specific conditions, or simply uncertain whether local integrated care boards will fund a prescription even if they write one.
The result is that patients who need cannabis-based medicine and do not fit one of three narrow NHS criteria have one realistic option: pay privately.
How Much Does a Private Medical Cannabis Prescription Actually Cost in the UK?
Private access to medical cannabis in the UK carries costs that accumulate fast. An initial consultation with a specialist clinic typically runs around £200. Follow-up appointments, which are required regularly to monitor progress and renew prescriptions, cost around £95 per quarter, according to MEDCANN Pharmacy’s 2025 pricing data.
The medication itself is where costs vary most. Monthly prescription costs typically range from £150 to £800 or more depending on the product type, dosage, and potency. Cannabis flower (10g) generally costs £50 to £150, oils run £60 to £200 for 10ml, and capsules sit around £70 to £250 for 30 units. Many patients use a combination of products, which pushes totals higher.
Charlotte Caldwell frames this reality plainly: “The vulnerable chronically ill don’t have £400, £500, £800 or £1,000 a month to pay for private medicine.”
That is not a fringe observation. It is a structural problem. Chronic illness and low income frequently go together. Many patients living with the conditions that cannabis-based medicine treats most consistently, such as chronic pain, PTSD, treatment-resistant epilepsy, and MS spasticity, are also among those least likely to have disposable income for ongoing private healthcare. The medicine is legal. Access to it is rationed by wallet.
Who Gets Left Behind When Legal Medicine Costs £800 A Month?
Those who cannot afford private prescriptions are effectively left with three paths. They can go without treatment, they can rely on less effective alternatives, or they can source cannabis illegally.
Research from Releaf published in 2023 estimated that as many as 1.8 million people in the UK are sourcing cannabis illegally to manage health conditions. That number is contested and difficult to verify precisely, but it points to a significant gap between medical need and legal access.
As researchers writing in The Conversation noted in 2026, the result is a two-tier system in which “legality is shaped not just by medical need, but by economic means.” A person managing chronic pain with a prescribed cannabis product is legally protected. Someone using the same product without a prescription faces potential criminal sanctions, regardless of the therapeutic reason behind it. And the difference between those two situations is often just money.
Street cannabis also carries risks that prescription products do not: unknown potency, potential contamination, no clinical oversight, and no quality control. A patient pushed to the illicit market because they cannot afford a prescription is not just losing legal protection. They are losing safety.
Why Are So Many UK Doctors Still Reluctant to Prescribe Cannabis-Based Medicines?
Even within the private sector, prescribing medical cannabis in the UK requires a doctor on the GMC Specialist Register. General practitioners cannot initiate a prescription for unlicensed cannabis-based products. That gatekeeping structure was intended to ensure clinical oversight, and it does. But it also severely limits how many prescribers are available and slows access at every stage.
For NHS prescribing, the barriers are layered further. A 2019 NHS England review into access to cannabis-based medicines found that doctors were concerned about a lack of evidence on effectiveness and safety, and that many were unaware of the guidance that existed. The review recommended establishing specialist networks and better education, but change has been slow.
By October 2024, the government’s position remained that improving the evidence base is the prerequisite for any NHS expansion. Two clinical trials of cannabis-based medicines for treatment-resistant epilepsy are currently funded by NHS England and the National Institute for Health and Care Research, but results take time and translate into policy even more slowly.
How Does UK Patient Access Compare to Germany and Australia?
The comparison with other countries is where UK policy looks most clearly out of step. Germany now has more than 372,000 medical cannabis patients, according to 2025 data. German patients can access prescriptions through their GP, and insurance coverage is available, except the recent removal of cannabis flower. The system is normalized, costs are lower, and access does not depend on private income.
Australia’s trajectory is even more striking. Australian medical cannabis patients numbered around 18,000 in 2019. By early 2024, that figure had grown to more than one million, supported by approximately 5,700 active prescribers.
The UK’s medical cannabis market is the second largest in Europe by revenue, worth around 269 million euros as of 2025. Britain exports cannabis-based products internationally while tens of thousands of domestic patients who might benefit from them cannot access or afford a prescription. That is a contradiction that is hard to rationalize.
What Would It Take to Close the UK’s Medical Cannabis Access Gap?
Several things would need to shift, and none of them are technically impossible. What they require is political will.
A study by the Centre for Economics and Business Research estimated that wider NHS access could unlock up to £13.3 billion for the UK economy over ten years through improved health outcomes and greater ability to work.
The financial case for expanding NHS access is documented. The clinical case, while still evolving, is strong enough in several conditions to have driven private prescribing to nearly 660,000 prescriptions in a single year. The remaining obstacle is institutional inertia and a policy framework that has not been updated since 2018.
Advocates and clinicians point to several practical steps: allowing GP referrals within specialist networks rather than requiring only GMC Specialist Register initiation, expanding the list of conditions routinely eligible for NHS consideration, and building the evidence base through funded trials rather than waiting for it to appear.
Charlotte Caldwell’s position is clear. Billy’s outcome proves the medicine works for some patients. The system that produced that outcome, an NHS prescription following years of advocacy and a legal battle, should not require a family to fight a national campaign to access. It should just be medicine.
What the UK’s Medical Cannabis Access Gap Means Right Now
Eight years after the law changed, the UK has a medical cannabis system that functions for those who can pay and fails those who cannot. Roughly 80,000 to 90,000 people are accessing cannabis-based medicine privately, many spending hundreds of pounds every month for a treatment that a specialist considers clinically appropriate. Meanwhile, only around 5,000 NHS prescriptions for licensed products were issued in the community in the whole of 2023.
Billy Caldwell’s story is genuinely good news. He is thriving. Charlotte Caldwell fought for years to make that possible, and the law she helped change is real. What it has not done, what the system has not done, is extend that same access to the families who cannot mount a national campaign and cannot pay £800 a month for medicine they legally qualify to receive.
Legal access without affordable access is still a gap. That gap is still open, and it is costing patients every month.
Frequently Asked Questions
In the UK, NHS cannabis-based medicine prescriptions are only available for three specific conditions: severe treatment-resistant epilepsy, MS-related muscle spasticity, and chemotherapy-induced nausea and vomiting — and only after other treatments have failed. Beyond these conditions, NHS prescribing is rare, leaving most patients to seek private prescriptions instead.
Private medical cannabis prescriptions in the UK typically cost between £150 and £800+ per month, varying by product, dosage, and potency. Those using multiple products often pay more, with advocate Charlotte Caldwell noting that many families spend £400 to £1,000 monthly.
The NHS only routinely prescribes medical cannabis for severe epilepsy, MS spasticity, and chemotherapy-induced nausea. Private clinics, however, can legally prescribe it for a broader range of conditions, including chronic pain, PTSD, anxiety, Parkinson’s, Crohn’s disease, fibromyalgia, endometriosis, and sleep disorders.
The UK government stated in October 2024 that until the evidence base improves, NHS prescribers will remain cautious and routine funding decisions cannot be made. Structural barriers also play a role: only GMC Specialist Register doctors can initiate unlicensed cannabis-based medicine prescriptions, many clinicians lack training in dosing and monitoring, and local integrated care boards must approve funding on a case-by-case basis.
